Smoking and antidepressants pharmacokinetics: a systematic review by Oliveira, P et al.




pharmacokinetics: a systematic review
Pedro Oliveira1, Joana Ribeiro1, Helena Donato2 and Nuno Madeira1* 
Abstract 
Background: Despite an increasingly recognized relationship between depression and smoking, little is known 
about how smoking influences antidepressant response and treatment outcomes. The aim of this study was to sys-
tematically review the evidence of the impact of smoking on new-generation antidepressants with an emphasis on 
the pharmacokinetic perspective.
Methods: We present a systematic review of clinical trials comparing the serum levels of new-generation antidepres-
sants in smokers and nonsmokers. Data were obtained from MEDLINE/PubMed, Embase, and other sources. Risk of 
bias was assessed for selection, performance, detection, attrition, and reporting of individual studies.
Results: Twenty-one studies met inclusion criteria; seven involved fluvoxamine, two evaluated fluoxetine, sertraline, 
venlafaxine, duloxetine or mirtazapine, and escitalopram, citalopram, trazodone and bupropion were the subject of a 
single study. No trials were found involving other common antidepressants such as paroxetine or agomelatine. Serum 
levels of fluvoxamine, duloxetine, mirtazapine and trazodone were significantly higher in nonsmokers compared with 
smokers.
Conclusions: There is evidence showing a reduction in the concentration of serum levels of fluvoxamine, duloxetine, 
mirtazapine and trazodone in smoking patients as compared to nonsmokers. The evidence regarding other com-
monly used antidepressants is scarce. Nonetheless, smoking status should be considered when choosing an antide-
pressant treatment, given the risk of pharmacokinetic interactions.
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Background
One-quarter of the general population, 40–50% of people 
with depression and 70–80% of those with schizophrenia 
smoke [1, 2]. Major depressive disorder (MDD) is a com-
mon psychiatric disease and a major public health prob-
lem. It has been projected to become the leading cause 
of disability and the second leading contributor to the 
global burden of disease and overall mortality by the year 
2020; according to the recent epidemiologic data, about 
10% of world population suffers with depression [3]. The 
advent of antidepressants (AD), starting with imipramine 
in 1958, has revolutionized the treatment of depression; 
yet this first generation of AD had an unfavorable adverse 
effect profile that has improved significantly with the 
advent in the late 1980s of selective serotonin reuptake 
inhibitors (SSRI) and, some years later, of serotonin and 
noradrenaline reuptake inhibitors (SNRI) and others like 
mirtazapine, trazodone, agomelatine and bupropion [4]. 
Given their favorable adverse effects profile, new-genera-
tion antidepressants are the first-line treatment of MDD. 
The mechanism of action and efficacy is similar between 
drugs of the same pharmacological class. However, 
there are considerable differences among interindividual 
responses to a given drug. Many theories tried to explain 
this variation but the most accepted is that clinical 
response is related to serum levels of the antidepressants. 
For many SSRI and other new-generation antidepressant 
drugs, a relationship between plasma concentrations and 
clinical effects is not reported [5]. However, serum levels 
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below therapeutic range could compromise the clini-
cal response [5]. The serum levels of antidepressants are 
essentially dependent on two variables: the intake dose 
of drug and the rate of elimination. The rate of elimina-
tion of antidepressants is almost exclusively dependent 
on their hepatic metabolization. The hepatic metabo-
lism of AD is made by cytochrome P450 (CYP) which is 
a group of many enzymes that exists in different amounts 
in human liver. Different antidepressants are metabolized 
by different subtypes of CYP and the amount of each 
CYP varies from person to person [6]. Thus, it is now 
accepted that the difference found in the response to an 
antidepressant could be correlated with serum concen-
trations. With the exception of tricyclic antidepressants, 
the correlation between plasmatic levels and the clinical 
outcome is still not consensual [7]. However, AGNP Con-
sensus Guidelines from 2011 attribute a level 2 of rec-
ommendation for therapeutic drug monitoring for SSRI 
(except paroxetine) and SNRI [7]. Despite the availability 
of techniques capable of quantifying the activity of CYP 
isozymes such as 1A2, 2B6, 2C9 and 3A4 [8], they are not 
commonly used in clinical practice. So, given the absence 
of clinical indicators as relating to the higher or lower 
individual activity of each CYP, often the choice is made 
based on clinical experience with the particular drug and 
previous response of the individual to antidepressants in 
the past. Such imprecision can lead to the inappropri-
ate use of drugs, not only wasting time until an adequate 
remission of depression but also causing iatrogenic harm, 
jeopardizing patient trust in antidepressant treatments.
There are 4000 chemical compounds found in cigarette 
smoke and 43 have been identified to be carcinogenic. 
Cigarette smoke constituents have been shown to stimu-
late or induce hepatic CYP isozymes, which play a central 
role in drug metabolism. Polycyclic aromatic hydrocar-
bons (PAH) from cigarette smoke are responsible for the 
induction of CYP isozymes. PAHs have been shown to 
induce CYP1A1, CYP1A2 and CYP2E1 [9].
Given the possibility that some antidepressants are 
metabolized by CYP induced or inhibited by substances 
in tobacco, their identification can be a guide for drug ini-
tial choice in smoking patients, allowing a more accurate 
antidepressant selection and consequently improving the 
pharmacologic treatment of depression in smokers.
Cigarette smoking can affect the clinical manage-
ment of patients with psychiatric disorders because of 
the pharmacokinetic and pharmacodynamical changes; 
it can cause to various psychotropic drugs. This article 
reviews the impact of smoking on new-generation anti-
depressants with an emphasis on the pharmacokinetic 
perspective. It also seeks to provide critical information 
on whether such variations should influence antidepres-
sant choice in this population.
Methods
This review was performed according to the PRISMA 
guidelines [10], thus providing a comprehensive frame-
work which objectively assesses indicators of quality and 
risk of biases of included studies.
All original studies investigating the difference between 
the levels of any new-generation antidepressive agents 
(SSRI, SNRI, trazodone, mirtazapine, bupropion or ago-
melatine) and the smoking status were eligible for this 
systematic review. Further criteria adopted were: (1) pub-
lication date between January 1970 and June 2016, (2) 
empirical study, (3) written in English or Portuguese lan-
guage, (4) published in a scholarly peer-reviewed journal, 
(5) studies that determined serum levels within a steady 
state, and (6) comparison of serum levels between 2 
groups—smokers and nonsmokers. Additionally, studies 
were excluded from review if they were: (1) single-case 
report, (2) review articles, (3) repeated study population, 
(4) comparisons involving combinations of drugs, (5) ani-
mal studies, and (6) trials involving only metabolites.
Studies were identified by searching relevant papers 
via PubMed/MEDLINE (http://www.ncbi.nlm.nih.gov/
pubmed), Cochrane Library and EMBASE using the fol-
lowing keywords: (“antidepressive agents”) AND (smok*). 
Finally, reference lists of retrieved studies were hand 
searched to identify any additional relevant studies. Key-
words and combination of keywords were used to search 
the electronic databases and were organized following 
the population intervention comparison outcome (PICO) 
model (Fig. 1). In this model, the search strategy can be 
organized based on the topics: population (P), interven-
tion (I), control group (C), and outcome (O) and several 
searches in the aforementioned databases.
After performing the initial literature searches, each 
study title and abstract was screened for eligibility by 
the first author. Full text of all potentially relevant stud-
ies were subsequently retrieved and further examined for 
eligibility. The PRISMA flow diagram (Fig.  1) provides 
more detailed information regarding the selection pro-
cess of studies. Information from the included studies 
was then analyzed and recorded in an electronic spread-
sheet designed by the first author. Different types of data 
were extracted from each study including: (a) country in 
which the data were collected and participants’ charac-
teristics, (b) number of subjects, (c) number of smokers, 
(d) age average, (e) percentage of males, (f ) main results 
(g) intervention protocol, (h) risk of bias in individual 
studies, and (i) limitations among others. The Cochrane 
Collaboration’s tool for assessing risk of bias was adopted 
to evaluate the risk of bias in individual studies [11]. The 
following risk of biases was analyzed: (1) selection bias, 
(2) performance bias, (3) detection bias, (4) attrition bias, 
and (5) reporting bias.
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Results
Twenty-one articles were included in this review: seven 
are about fluvoxamine (FLV) [18–24], two about fluoxe-
tine (FLX) [12, 13], sertraline [14, 15], venlafaxine (VEN) 
[25, 26], duloxetine [27, 28] and mirtazapine [30, 31], one 
about escitalopram [16], citalopram [17], trazodone [29] 
and bupropion [32]. No studies were found about parox-
etine, milnacipran or agomelatine.
Eight studies were from Sweden, six were from Japan, 
four from Germany, two were from the United States 
of America (USA), and one from France and Switzer-
land. The studies reviewed included 2375 participants 
of which 733 were smokers. In terms of gender distribu-
tion, the vast majority of the studies reviewed recruited 
more female participants (64.31%) than male participants 
(35.69%). The average age of the subjects included in the 
studies is 45.53  years. A summary of results is given in 
Table  1 and the risk of bias in individual studies based 
on Cochrane Collaboration’s tool for assessing risk of 
bias is given in Table  2. As shown in Table  2, selection 
and reporting bias are the most frequent, with seven of 
twenty-one studies assessed with high risk for selection 
bias and four with high risk of reporting bias. No detec-
tion and attrition bias were found, although the risk of 
bias was not always clear.
Discussion
As mentioned above, tobacco interferes with drug 
metabolism essentially by the action of PAH that have 
effects through the induction of CYP 1A1, CYP1A2 and 
CYP2E1 [9].
All the antidepressants evaluated are metabolized in 
the liver by different types of cytochromes. With respect 
to SSRIs, citalopram is metabolized by CYP 2C19 and 
3A4 [33], fluoxetine by 2D6, 3A4 and 2C9 [33], fluvoxam-
ine by 1A2 and 2D6 [33], escitalopram by 2C19, 2D6 and 
3A4 [16], and sertraline by 2D6, 3A4, 2C9 and 2C19 [33]. 
Regarding SNRI, venlafaxine is metabolized by CYP 2D6, 
3A4 and 2C9 [33], and duloxetine by 2D6 and 1A2 [27]. 
Trazodone is metabolized by CYP 2D6 [29], mirtazapine 
by 1A2, 2D6 and 3A4 [31], and bupropion by 2B6 [32].
SSRI, except fluvoxamine, have little research on the 
effects of tobacco consumption in their serum levels. The 
trials performed with sertraline, escitalopram and citalo-
pram showed no influence of smoking on their pharma-
cokinetics. However, the study on citalopram was based 
on a population in a restricted age group (all subjects 
were younger than 21  years) and studies regarding ser-
traline and escitalopram were not randomized and had 
many important limitations like the possibility of inter-
actions with other drugs. The fluoxetine concentrations 
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Fig. 1 PRISMA flow diagram of the study selection process
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did not differ between the two study groups but the lev-
els of its active metabolite, norfluoxetine, were higher in 
the group of smokers. Since norfluoxetine is an active 
metabolite, such association may impact the response 
of patients to take fluoxetine as well as implications with 
increased half-life of this molecule, which is already 
long, for example, by drug bioaccumulation and the abil-
ity to induce serotonin syndromes. Fluvoxamine has the 
greater evidence of decreased serum levels when associ-
ated with tobacco consumption. Although not proved, 
most studies suggest that there may be an association 
between the biotransformation of fluvoxamine and the 
activity of CYP1A2. It could not be excluded, however, 
that other factors may account for such a difference. Rea-
sons include a possible association between smoking and 
fluvoxamine absorption, as well as between smoking and 
the elimination of fluvoxamine by other metabolic path-
ways. Further studies are, therefore, needed to clarify the 
role of CYP1A2 and other specific CYP in fluvoxamine 
metabolism and to elucidate which of the various meta-
bolic steps could be dependent on CYP1A2. The recom-
mended therapeutic reference range of fluvoxamine is 
60–230 ng/mL [5]. Several studies have shown relations 
between plasma concentrations and clinical effects [5]. 
As a possible bias of these studies we highlight that most 
data involves Japanese individuals. This may influence 
the effect size, given, that this population presents quan-
titative differences, sometimes substantial, the various 
cytochrome P450 enzymes.
Assays for the SNRIs provide more consistent results 
than those involving SSRIs. Research on venlafaxine and 
duloxetine has similar designs, making result compari-
son easier and strengthening results. In both studies with 
venlafaxine, serum levels of both study groups showed 
no significant differences. Both pointed to a significant 
decrease in ODV levels. However, the pharmacodynami-
cal effects of this are not completely understood, though 
many studies point to considerably weaker inhibition of 
serotonin and noradrenaline reuptake pumps when com-
pared with venlafaxine itself [34]. For duloxetine, avail-
able data suggest a decrease in serum concentrations 
caused by tobacco consumption. In this drug, the avail-
able evidence is strong, based on multicenter randomized 
trials, involving a broad number of evaluated subjects. 
The effects of smoking status on duloxetine bioavail-
ability can be attributed to the mechanism of duloxetine 
metabolism primarily by CYP1A2 enzyme. Smoking 
increases the expression of CYP1A2, which may explain 
the lower duloxetine bioavailability noted in smokers. 
The recommended therapeutic reference range of dulox-
etine is 30–120  ng/mL [5]. So far there is only a single 
retrospective analysis on plasma concentrations and 
Table 2 Assessment of risk of bias in individual studies
+ high risk of bias, – low risk of bias, ? unclear risk of bias
Study Selection bias Performance bias Detection bias Attrition bias Reporting bias
Lundmarck et al. [12] − − − ? −
Koelch et al. [13] ? ? − − +
Lundmarck et al. [14] − − − ? −
Taurines et al. [15] ? ? − − +
Reis et al. [16] ? ? − ? +
Reis et al. [17] + ? − ? ?
Spigset et al. [18] − − − − −
Carrillo et al. [19] − − − − ?
Yoshimura et al. [20] − + − − ?
Gerstenberg et al. [21] − − − ? ?
Sugahara et al. [22] ? ? − − ?
Katoh et al. [23] + − − − ?
Suzuki et al. [24] + − − − −
Reis et al. [25] + ? − ? ?
Unterecker et al. [26] − − − ? −
Fric et al. [27] + − − ? −
Lobo et al. [28] − − − − −
Ishida et al. [29] ? − − − −
Lind et al. [30] − − − − −
Sirot et al. [31] + − ? − −
Hsyu et al. [32] + − − − +
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clinical effects that has shown concentration-dependent 
improvement [5].
Data suggest a decrease in serum concentrations of tra-
zodone caused by tobacco consumption and no influence 
in serum concentrations of trazodone’s active metabolite 
m-chloro-phenylpiperazine (mCPP). This reduction could 
be due to the enhancement of hydroxylation and N-oxi-
dation of trazodone caused by PAH from cigarette smoke 
[29]. A concentration–response relationship for trazo-
done has not been established [29]; however, one study 
has suggested the presence of a linear relationship [35].
The two studies that evaluated the effect of smoking on 
mirtazapine’s pharmacokinetics show significantly lower 
mirtazapine and their main active metabolites  (S-mir-
tazapine and R-N-desmethylmirtazapine) serum levels 
in smokers  than in  nonsmokers. In  vitro tomography 
study has shown that CYP1A2 is involved in 8-hydroxyla-
tion and possibly N-oxidation of mirtazapine [30]. Addi-
tionally, uridine diphosphate glucuronosyltransferases, 
another enzyme involved in the metabolism of mirtazap-
ine, are inducible by smoking [30]. The recommended 
therapeutic reference range of mirtazapine is 30–80 ng/
mL [5]. In a study on patients with depression, respond-
ers to mirtazapine treatment presented higher plasma 
concentrations than non-responders [36].
In the study with bupropion serum levels, both study 
groups showed no significant differences [32]. This study 
only evaluated daily doses of 150  mg of bupropion, 
reporting nothing on higher doses of drug.
Most antidepressants adverse effects are dose depend-
ent, and some arise only when serum antidepressant 
levels reach a certain value [5]. Given that inhibition of 
CYP1A2 by tobacco smoke may decrease serum levels 
of some drugs, smoking cessation in heavy smokers tak-
ing such medication might lead to increased serum lev-
els. Such an increase may cause adverse effects hitherto 
absent.
As mentioned above, the most frequent bias found was 
related with selection bias, which can lead to an over/
underestimation of the obtained results. Increasing the 
sample size and the use of control groups are recom-
mended strategies to decrease this risk in future studies.
Conclusions
Despite numerous limitations in most studies, avail-
able evidence indicates a reduction in the concentration 
of serum levels of fluvoxamine, duloxetine, trazodone 
and mirtazapine in smoking patients when compared 
to nonsmokers. These differences raise the possibility 
of a semi-directed choice in antidepressant treatments, 
adapting the dose of these drugs and being aware of 
possible appearances of side effects after smoking 
cessation.
A personalized pharmacological treatment of depres-
sion could be made possible in a nearby future, guided 
by increasingly common and less expensive genotyp-
ing tools. For now, treatment personalization could be 
based on identifying phenotypes or external variables 
that influence antidepressant response or side effects. 
Further research is needed to improve our knowledge on 
the influence of smoking in depression pharmacological 
treatment.
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